DIVISLAB

Shares of Divis Laboratories experienced a notable downturn in Friday's session. The stock price fell 3.45% to Rs 5,920.00, driven by high volume. The stock is among the top losers on the Nifty Next 50 index. This decline reflects a shift in investor sentiment, with the stock experiencing a surge in ***** revenue for Divis Laboratories showed consistent growth over the past five years. Consolidated revenue for the year-ending March 2025 stood at Rs 9,360 Crore, a notable increase compared to Rs 7,845 Crore in March 2024. Similarly, the company's net profit increased to Rs 2,191 Crore in March 2025 from Rs 1,600 Crore in March 2024. The earnings per share (EPS) also rose from Rs 60.27 in March 2024 to Rs 82.53 in March ***** company’s quarterly performance also reveals positive trends. For the quarter-ending June 2025, the revenue stood at Rs 2,410 Crore, up from Rs 2,118 Crore in June 2024. The net profit for the same period was Rs 545 Crore, compared to Rs 430 Crore in the corresponding quarter of the previous year. The EPS increased from Rs 16.20 in June 2024 to Rs 20.49 in June ***** financial ratios for Divis Laboratories indicate a strong financial position. The company reported a debt-to-equity ratio of 0.00 for the year-ending March 2025. The basic EPS stood at Rs 82.53, and the diluted EPS was also Rs 82.53 for the same period. The book value per share (excluding revaluation reserve) was Rs 564.87. The P/E ratio as of March 2025 was 69.98, and the P/B ratio was 10.22. Divis Laboratories has consistently rewarded its shareholders with dividends. The company announced a final dividend of Rs 30 per share (1500%) on May 19, 2025, with an effective date of July 25, 2025. Similar dividends were announced in previous years as well.